首页> 外国专利> METHOD FOR PREDICTING THE RISK OF POOR TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH INVASIVE BREAST CANCER

METHOD FOR PREDICTING THE RISK OF POOR TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH INVASIVE BREAST CANCER

机译:预测浸润性乳腺癌患者对新辅助化疗不良反应的风险的方法

摘要

FIELD: medicine.;SUBSTANCE: invention is a method for predicting the risk of a poor tumor response to neoadjuvant chemotherapy (NAC) in patients with invasive breast carcinoma, characterized in that the value of the parameter Y in the regression equation is calculated using the formula Y=-4.88+10*X1-32.36*X2+6.81*X3+38.28*X4, where X1 is the degree of malignancy: X1=1 with low, X1=2 with moderate, X1=3 with high degree of malignancy; X2 – the state of the patient's menstrual function: X2 = 1 with maintaining menstrual function, X2 = 2 with menopause; X3 – the threshold value of circulating tumor cells (CTC) without signs of epithelial-mesenchymal transition (EMT) before the start of treatment: X3=0 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin- less than 0.19 cells/mcl, X3=1 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin- more than or equal to 0.19 cells/mcl; X4 – is the threshold value of the CTC with a sign of EMT before the start of treatment: X4=0 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin+ less than 0.24 cells/mcl, X4=1 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin+ more than or equal to 0.24 cells/mcl; further, the value of the probability of the risk of a poor response to neoadjuvant chemotherapy P is determined by the formula P=eY/(1+eY), where e – is a mathematical constant equal to 2.72, and with probability P≥0.5, high risk is determined, and if the probability is P0.5, there is low risk of a poor response to neoadjuvant chemotherapy.;EFFECT: invention provides improved accuracy and informativeness of prediction.;1 cl, 2 ex, 3 tbl
机译:发明领域:本发明是一种预测浸润性乳腺癌患者对新辅助化疗(NAC)的不良肿瘤反应风险的方法,其特征在于,回归方程中的参数Y的值使用公式Y = -4.88 + 10 * X1-32.36 * X2 + 6.81 * X3 + 38.28 * X4,其中X1是恶性程度:X1 = 1恶性程度高,X1 = 2恶性程度,X1 = 3恶性程度高; X2 –患者月经状态:X2 = 1并保持月经功能,X2 = 2并停经; X3 –治疗开始前无上皮-间质转化(EMT)迹象的循环肿瘤细胞(CTC)阈值:X3 = 0,表型为EpCam + CD45-CD44-CD24-Ncadherin的细胞含量小于表型为EpCam + CD45-CD44-CD24-Ncadherin-的细胞含量大于或等于0.19个细胞/mcl,X3=0.19个细胞/ mcl; X4 –是开始治疗前具有EMT征兆的CTC阈值:X4 = 0,表型为EpCam + CD45-CD44-CD24-Ncadherin +的细胞含量小于0.24细胞/ mcl,X4 = 1表型EpCam + CD45-CD44-CD24-Ncadherin +的细胞含量大于或等于0.24细胞/ mcl;此外,对新辅助化疗P反应不良的风险的可能性值由公式P = e Y /(1 + e Y )确定,其中e –是一个等于2.72的数学常数,概率P≥0.5,则确定为高风险,如果概率P <0.5,则对新辅助化疗反应不良的风险较低。和预测的信息性。; 1 cl,2 ex,3 tbl

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号